All Stories

  1. Has the HCV cascade of care changed among people who inject drugs in England since the introduction of direct-acting antivirals?
  2. Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis
  3. Identifying priority populations for HIV interventions using acquisition and transmission indicators: a combined analysis of 15 mathematical models from 10 African countries
  4. Tuberculosis and people who use drugs: why focus on this overlooked population is important and why adapted interventions are necessary
  5. Supervised Injecting Room Cohort Study (SIRX): study protocol
  6. HIV incidence and factors associated with HIV risk among people who inject drugs engaged with harm-reduction programmes in four provinces in South Africa: a retrospective cohort study
  7. From conceptualising to modelling structural determinants and interventions in HIV transmission dynamics models: a scoping review and methodological framework for evidence-based analyses
  8. Modeling the impact of the COVID-19 pandemic on achieving HCV elimination amongst young and unstably housed people who inject drugs in San Francisco
  9. Sex and gender differences in hepatitis C virus risk, prevention, and cascade of care in people who inject drugs: systematic review and meta-analysis
  10. Testing and Treatment Interventions in Community Settings Key to Controlling a Recent Human Immunodeficiency Virus Outbreak Among People Who Inject Drugs in Glasgow: A Modeling Study
  11. Mathematical models of COVID-19 vaccination in high-income countries: A systematic review
  12. Kentucky Outreach Service Kiosk (KyOSK) Study protocol: a community-level, controlled quasi-experimental, type 1 hybrid effectiveness study to assess implementation, effectiveness and cost-effectiveness of a community-tailored harm reduction kiosk on H...
  13. Trends and factors associated with illicit drug use in South Africa: Findings from multiple national population-based household surveys, 2002–2017
  14. Comparison of Empirically Derived and Model-Based Estimates of Key Population HIV Incidence and the Distribution of New Infections by Population Group in Sub-Saharan Africa
  15. Measuring HIV Acquisitions Among Partners of Key Populations: Estimates From HIV Transmission Dynamic Models
  16. Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination
  17. Eliminating HIV in the UK among men who have sex with men
  18. Associations Between Sexual Behavior Stigma and HIV Risk Behaviors, Testing, Treatment, and Infection Among Men Who have Sex with Men in Ukraine
  19. Incarceration history is associated with HIV infection among community‐recruited people who inject drugs in Europe: A propensity‐score matched analysis of cross‐sectional studies
  20. Mortality among individuals prescribed opioid-agonist therapy in Scotland, UK, 2011–20: a national retrospective cohort study
  21. Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis
  22. Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis
  23. Trends in HIV incidence following scale-up of harm reduction interventions among people who inject drugs in Kachin, Myanmar, 2008–2020: analysis of a retrospective cohort dataset
  24. Modelling the impact and cost‐effectiveness of non‐governmental organizations on HIV and HCV transmission among people who inject drugs in Ukraine
  25. The population impact of herpes simplex virus type 2 (HSV-2) vaccination on the incidence of HSV-2, HIV and genital ulcer disease in South Africa: a mathematical modelling study
  26. Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya
  27. Impact and cost‐effectiveness of the national scale‐up of HIV pre‐exposure prophylaxis among female sex workers in South Africa: a modelling analysis
  28. Interventions to prevent HIV and Hepatitis C among people who inject drugs: Latest evidence of effectiveness from a systematic review (2011 to 2020)
  29. Prison‐based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: a modelling study
  30. Modelling the impact of HIV and hepatitis C virus prevention and treatment interventions among people who inject drugs in Kenya
  31. Impact and cost-effectiveness of non-governmental organizations on the HIV epidemic in Ukraine among MSM
  32. A cross‐sectional study comparing men who have sex with men and inject drugs and people who inject drugs who are men and have sex with men in San Francisco: Implications for HIV and hepatitis C virus prevention
  33. Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO
  34. Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya
  35. The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study
  36. Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis
  37. Evaluating the impact and cost-effectiveness of scaling-up HCV treatment among people who inject drugs in Ukraine
  38. Comparing men who have sex with men and inject drugs and people who inject drugs who are men and have sex with men in San Francisco: Implications for HIV and hepatitis C virus prevention
  39. Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 – is the precautionary principle applicable?
  40. Modeling the population‐level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia
  41. Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania
  42. Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection
  43. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison
  44. Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP‐C Treatment as Prevention Study in Prisons
  45. An intensive model of care for hepatitis C virus screening and treatment with direct‐acting antivirals in people who inject drugs in Nairobi, Kenya: a model‐based cost‐effectiveness analysis
  46. Overlapping Key Populations and HIV Transmission in Tijuana, Mexico: A Modelling Analysis of Epidemic Drivers
  47. Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis
  48. Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis
  49. Epidemiology and transmission of COVID-19 in cases and close contacts in Georgia in the first four months of the epidemic
  50. Modelling the Impact of Prevention and Treatment Interventions on HIV and Hepatitis C Virus Transmission Among People Who Inject Drugs in Kenya
  51. Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky
  52. Estimating the contribution of key populations towards HIV transmission in South Africa
  53. Is contact between men who have sex with men and non‐governmental organizations providing harm reduction associated with improved HIV outcomes?
  54. Injecting risk behaviours amongst people who inject drugs: A global multi-stage systematic review and meta-analysis
  55. Has resourcing of non‐governmental harm‐reduction organizations in Ukraine improved HIV prevention and treatment outcomes for people who inject drugs? Findings from multiple bio‐behavioural surveys
  56. Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review
  57. Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence
  58. Frequency of injecting among people who inject drugs: A systematic review and meta-analysis
  59. Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis
  60. Prevalence and burden of HBV co‐infection among people living with HIV: A global systematic review and meta‐analysis
  61. The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis
  62. Global patterns of opioid use and dependence: harms to populations, interventions, and future action
  63. Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison
  64. Inflammation, Glutamate, and Cognition in Bipolar Disorder Type II: A Proof of Concept Study
  65. A global meta-analysis on HIV, hepatitis C and hepatitis B among people who inject drugs – do gender differences vary by country-level indicators?
  66. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis
  67. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs
  68. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review
  69. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland
  70. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia
  71. The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?
  72. Public health and international drug policy
  73. Incarceration of People who inject Drugs – Modelling its Role in HCV Transmission and the Impact of Scaled-Up HCV Treatment in Prisons
  74. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments
  75. P076: The role of a hepatitis C virus vaccine: modelling the benefits alongside direct‐acting antiviral treatments